Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon Skin Descaler

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s newest product, Loyon Skin Descaler.  Loyon is intended to manage skin scaling experienced with various types of dermatoses.

Loyon Skin Descaler is a unique and patented combination of the dry emollient Cetiol CC and the medical silicone oil dimethicone. The product is easily applied and spreads exceptionally well into the cracks and crevices of the scale due to its low surface tension.  U.S. commercialization via Sonoma’s dermatology division IntraDerm Pharmaceuticals’ 30-plus-person direct sales team is slated for summer 2017.

“Loyon Skin Descaler has demonstrated an impressive level of efficacy in the management of multiple dermatoses including psoriasis capitis and seborrheic dermatitis since first being commercialized in Europe in 2014,” said Jeffrey Day, president of IntraDerm Pharmaceuticals. “Nearly a quarter of the U.S. population is afflicted with scaling associated with various skin dermatoses and we believe this product, once launched, will provide this community with a most novel tool for assisting with scale removal in their patient populations.”